| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Esophageal cancer.
|
N Engl J Med
|
2003
|
15.23
|
|
2
|
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
|
Blood
|
2002
|
12.46
|
|
3
|
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.
|
J Clin Oncol
|
2004
|
9.73
|
|
4
|
Systemic therapy for colorectal cancer.
|
N Engl J Med
|
2005
|
8.94
|
|
5
|
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
|
J Clin Oncol
|
2010
|
5.21
|
|
6
|
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
|
JAMA
|
2008
|
4.61
|
|
7
|
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
|
J Clin Oncol
|
2007
|
4.32
|
|
8
|
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Clin Oncol
|
2006
|
4.27
|
|
9
|
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
|
J Clin Oncol
|
2005
|
3.50
|
|
10
|
Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians.
|
Acad Med
|
2012
|
3.28
|
|
11
|
Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection.
|
Ann Surg Oncol
|
2003
|
3.27
|
|
12
|
Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence.
|
Ann Intern Med
|
2003
|
3.01
|
|
13
|
A compendium of potential biomarkers of pancreatic cancer.
|
PLoS Med
|
2009
|
3.00
|
|
14
|
Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
|
J Clin Oncol
|
2009
|
2.94
|
|
15
|
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
|
JAMA
|
2007
|
2.84
|
|
16
|
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
|
J Clin Oncol
|
2008
|
2.74
|
|
17
|
Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
|
JAMA
|
2008
|
2.67
|
|
18
|
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
|
Gastroenterology
|
2006
|
2.63
|
|
19
|
Systemic treatment of colorectal cancer.
|
Gastroenterology
|
2008
|
2.62
|
|
20
|
Impact of diabetes mellitus on outcomes in patients with colon cancer.
|
J Clin Oncol
|
2003
|
2.52
|
|
21
|
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001.
|
J Clin Oncol
|
2006
|
2.49
|
|
22
|
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
|
J Clin Oncol
|
2006
|
2.48
|
|
23
|
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2005
|
2.47
|
|
24
|
Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought.
|
J Clin Oncol
|
2012
|
2.45
|
|
25
|
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2011
|
2.40
|
|
26
|
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.
|
J Clin Oncol
|
2004
|
2.30
|
|
27
|
Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
Blood
|
2006
|
2.29
|
|
28
|
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
|
J Clin Oncol
|
2006
|
2.29
|
|
29
|
Characterization of sporadic colon cancer by patterns of genomic instability.
|
Cancer Res
|
2003
|
2.24
|
|
30
|
Adjuvant treatment of colorectal cancer.
|
CA Cancer J Clin
|
2007
|
2.22
|
|
31
|
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
|
J Clin Oncol
|
2007
|
2.22
|
|
32
|
Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.
|
Cancer
|
2003
|
2.19
|
|
33
|
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.
|
Am J Clin Oncol
|
2004
|
2.18
|
|
34
|
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
|
J Clin Oncol
|
2005
|
2.17
|
|
35
|
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2005
|
2.16
|
|
36
|
NCCN clinical practice guidelines in oncology. Colorectal cancer screening.
|
J Natl Compr Canc Netw
|
2010
|
2.13
|
|
37
|
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers.
|
Cancer Res
|
2004
|
2.10
|
|
38
|
Perspective: a culture of respect, part 2: creating a culture of respect.
|
Acad Med
|
2012
|
2.06
|
|
39
|
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2009
|
2.02
|
|
40
|
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
|
J Clin Oncol
|
2006
|
1.94
|
|
41
|
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
|
J Clin Oncol
|
2006
|
1.89
|
|
42
|
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
|
J Clin Oncol
|
2004
|
1.86
|
|
43
|
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
|
J Clin Oncol
|
2012
|
1.84
|
|
44
|
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089.
|
Ann Intern Med
|
2002
|
1.75
|
|
45
|
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q.
|
Cancer Biol Ther
|
2004
|
1.71
|
|
46
|
Merkel cell carcinoma.
|
J Clin Oncol
|
2002
|
1.71
|
|
47
|
US intergroup anal carcinoma trial: tumor diameter predicts for colostomy.
|
J Clin Oncol
|
2009
|
1.65
|
|
48
|
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2006
|
1.64
|
|
49
|
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2008
|
1.57
|
|
50
|
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.
|
Cancer Biol Ther
|
2004
|
1.57
|
|
51
|
A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
|
Ann Surg Oncol
|
2007
|
1.46
|
|
52
|
Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer.
|
J Natl Cancer Inst
|
2002
|
1.38
|
|
53
|
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
|
J Clin Oncol
|
2009
|
1.38
|
|
54
|
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
|
Cancer J
|
2002
|
1.33
|
|
55
|
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
|
J Clin Oncol
|
2004
|
1.32
|
|
56
|
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
|
J Clin Oncol
|
2011
|
1.31
|
|
57
|
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2007
|
1.28
|
|
58
|
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis.
|
Int J Radiat Oncol Biol Phys
|
2002
|
1.27
|
|
59
|
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
|
Int J Gastrointest Cancer
|
2003
|
1.26
|
|
60
|
Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia.
|
Blood
|
2004
|
1.20
|
|
61
|
Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Natl Cancer Inst
|
2012
|
1.20
|
|
62
|
Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study.
|
J Clin Oncol
|
2004
|
1.20
|
|
63
|
Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
|
J Clin Oncol
|
2005
|
1.19
|
|
64
|
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
|
J Clin Oncol
|
2004
|
1.19
|
|
65
|
Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers.
|
Int J Cancer
|
2004
|
1.18
|
|
66
|
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
|
J Clin Oncol
|
2011
|
1.12
|
|
67
|
Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
1.12
|
|
68
|
Two steps forward in the treatment of colorectal cancer.
|
N Engl J Med
|
2004
|
1.12
|
|
69
|
Targeted therapy for advanced colorectal cancer--more is not always better.
|
N Engl J Med
|
2009
|
1.12
|
|
70
|
Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11).
|
Cancer
|
2010
|
1.09
|
|
71
|
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.
|
J Natl Cancer Inst
|
2011
|
1.06
|
|
72
|
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
|
Cancer
|
2002
|
1.06
|
|
73
|
Colorectal cancer screening.
|
J Natl Compr Canc Netw
|
2013
|
1.02
|
|
74
|
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
|
Cancer
|
2002
|
0.98
|
|
75
|
Follow-up strategies after curative resection of colorectal cancer.
|
Semin Oncol
|
2003
|
0.97
|
|
76
|
Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
|
Int J Oncol
|
2002
|
0.93
|
|
77
|
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.
|
J Natl Cancer Inst
|
2013
|
0.92
|
|
78
|
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
|
Clin Cancer Res
|
2009
|
0.90
|
|
79
|
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281).
|
J Clin Oncol
|
2008
|
0.89
|
|
80
|
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
|
Int J Radiat Oncol Biol Phys
|
2013
|
0.89
|
|
81
|
Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803.
|
J Clin Oncol
|
2010
|
0.89
|
|
82
|
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
|
Cancer
|
2010
|
0.88
|
|
83
|
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
|
Clin Cancer Res
|
2013
|
0.86
|
|
84
|
Colorectal Cancer Screening Clinical Practice Guidelines.
|
J Natl Compr Canc Netw
|
2006
|
0.86
|
|
85
|
A step forward in the treatment of advanced biliary tract cancer.
|
N Engl J Med
|
2010
|
0.85
|
|
86
|
A phase II study of docetaxel in patients with metastatic carcinoid tumors.
|
Cancer Invest
|
2004
|
0.83
|
|
87
|
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
|
Dig Dis Sci
|
2005
|
0.83
|
|
88
|
Gastrointestinal cancer in older patients.
|
Semin Oncol
|
2004
|
0.82
|
|
89
|
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2007
|
0.81
|
|
90
|
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.81
|
|
91
|
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.81
|
|
92
|
Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
|
Pancreatology
|
2012
|
0.79
|
|
93
|
Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist.
|
J Oncol Pract
|
2012
|
0.78
|
|
94
|
Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease.
|
Gastroenterol Clin North Am
|
2006
|
0.78
|
|
95
|
Cancer and leukemia group B gastrointestinal cancer committee.
|
Clin Cancer Res
|
2006
|
0.76
|
|
96
|
Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance.
|
Clin Colorectal Cancer
|
2013
|
0.76
|
|
97
|
Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.
|
Clin Cancer Res
|
2006
|
0.76
|
|
98
|
Reply to A. Grothey et al and R.S. Midgley et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
99
|
By the way, doctor. Cancer of the small intestine.
|
Harv Health Lett
|
2008
|
0.75
|
|
100
|
By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon cancer screening test that everybody should be getting instead of a regular colonoscopy? I thought it was kind of experimental.
|
Harv Health Lett
|
2010
|
0.75
|
|
101
|
The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future.
|
J Clin Oncol
|
2010
|
0.75
|
|
102
|
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
|
Cancer Invest
|
2003
|
0.75
|
|
103
|
By the way, doctor. We have screening tests for other cancers. How about pancreatic cancer?
|
Harv Health Lett
|
2009
|
0.75
|